Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.

Sharma A, Shah SR, Illum H, Dowell J.

Drugs. 2012 Dec 3;72(17):2207-22. doi: 10.2165/11640870-000000000-00000. Review.

PMID:
23116250
2.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
3.

Vemurafenib.

Garbe C, Abusaif S, Eigentler TK.

Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Review.

PMID:
24756795
4.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753
5.

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS.

Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Review.

6.

New RAF kinase inhibitors in cancer therapy.

Martin-Liberal J, Larkin J.

Expert Opin Pharmacother. 2014 Jun;15(9):1235-45. doi: 10.1517/14656566.2014.911286. Epub 2014 Apr 28. Review.

PMID:
24766074
7.

Dabrafenib therapy for advanced melanoma.

Trinh VA, Davis JE, Anderson JE, Kim KB.

Ann Pharmacother. 2014 Apr;48(4):519-29. doi: 10.1177/1060028013513009. Epub 2013 Nov 20. Review.

PMID:
24259661
8.

Vemurafenib for the treatment of melanoma.

Jordan EJ, Kelly CM.

Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24. Review.

PMID:
23094782
9.

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.

Martin-Liberal J, Larkin J.

Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252. Review.

PMID:
25686114
10.

Dabrafenib and its potential for the treatment of metastatic melanoma.

Menzies AM, Long GV, Murali R.

Drug Des Devel Ther. 2012;6:391-405. doi: 10.2147/DDDT.S38998. Epub 2012 Dec 11. Review.

11.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Jang S, Atkins MB.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Review.

PMID:
24080641
12.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
13.

Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Devji T, Levine O, Neupane B, Beyene J, Xie F.

JAMA Oncol. 2017 Mar 1;3(3):366-373. doi: 10.1001/jamaoncol.2016.4877. Review.

PMID:
27787543
14.

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.

Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.

Discov Med. 2015 Jun;19(107):455-61. Review.

15.

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.

Heakal Y, Kester M, Savage S.

Ann Pharmacother. 2011 Nov;45(11):1399-405. doi: 10.1345/aph.1Q363. Epub 2011 Oct 25. Review.

PMID:
22028422
16.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
17.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
18.

Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation.

Chapman PB.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e80. Review.

19.

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Vultur A, Villanueva J, Herlyn M.

Clin Cancer Res. 2011 Apr 1;17(7):1658-63. doi: 10.1158/1078-0432.CCR-10-0174. Epub 2011 Mar 29. Review.

20.

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.

Swaika A, Crozier JA, Joseph RW.

Drug Des Devel Ther. 2014 Jun 16;8:775-87. doi: 10.2147/DDDT.S31143. eCollection 2014. Review.

Supplemental Content

Support Center